

Claim Version with markings showing changes made

1. (Presently amended) A method of blocking or reducing physiological reaction in a mammal to the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of a therapeutically effective amount of a neurotoxin (CnT) ~~derived~~ isolated or purified from Clostridia sp.
2. (Original) The method of claim 1 wherein the mammal is a member of H. sapiens.
3. (Presently amended) The method of claim 2 wherein the neurotoxin is ~~derived~~ isolated or purified from a species of Clostridia selected from the group consisting of C. botulinum, C. butyricum, C. beratti, and C. tetani .
4. (Presently amended) The method of claim 3 wherein the neurotoxins (BoNT), isolated or purified ~~derived~~ from C. botulinum, are derived from serotypes A, B, C1, D, E, F and G
5. (Presently amended) The method of claim 3 wherein the neurotoxin (TeNT) is ~~is~~ isolated or purified ~~derived~~ from C.tetani.
6. (Original) The method of claim 1 wherein CnT is administered by contact with absorbant pledgets having CnT absorbed thereon.
7. (Original) The method of claim 1 wherein CnT is administered by contact with biodegradable carrier containing CnT .
8. (Original) The method of claim 1 wherein CnT is administered by injection.
9. (Original) The method of claim 1 wherein CnT is administered by myringotomy into tympanic membranes.
10. (Original) The method of claim 1 wherein CnT is administered by injection into the pterygoplatine space through the palate.
11. (Original) The method of claim 7 wherein CnT is administered to pass through the nasal wall to the sphenopalatine ganglia .
12. (Presently amended) The method of claim 1 wherein CnT is administered by inhalation of an aqueous mist containing ~~same~~ said CnT.

Deleted: t

Deleted: .

13. (Original) The method of claim 1 wherein CnT is administered by injection to the nasal mucosa.

14. (Presently amended) The method of claim 1 wherein CnT is administered by application of a suppository containing ~~same~~ said CnT.

15. (Presently amended) The method of claim 1 wherein the physiological reaction is manifested by a condition or symptoms selected from the group consisting of allergic rhinitis, infectious rhinitis, serous otitis media, sinusitis, pulmonary disease, food allergies, allergic dermatitis, ~~and~~ sneezing, coughing, itching and excess mucous secretion related to allergic reactions.

16. (Original) The method of claim 15 wherein the pulmonary disease is selected from the group consisting of bronchitis, emphysema and hyperactive asthma.

17. (Original) The method of claim 1 wherein CnT is administered by contact with absorbant* pledgets having CnT absorbed thereon.

Formatted: Bullets and Numbering

18. (Original) The method of claim 1 wherein the amount of CnT administered per* administration is between about 0.1 and about 1000 units per administration.

Formatted: Bullets and Numbering

19. (Original) The method of claim 1 wherein the amount of CnT administered per* administration is between about 1 and about 100 units per administration.

Formatted: Bullets and Numbering

20. 20. (Original) The method of claim 1 wherein the amount of CnT administered per* administration is between about 1 and about 20 units per administration.

Formatted: Bullets and Numbering

Claims 21-24 are cancelled